FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 08/2022”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the US-Biotech sector.
As of the top of August 2022, we establish the next present VC traits within the US-Biotech sector:
- In 2022, general Biotech funding within the USA has reached USD 21,632m up to now
- The highest 5 offers exceed USD 340m every, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Enterprise Companions (USA) is main the Prime 5 Traders (by deal quantity), adopted by 8VC (USA) and Alexandria Enterprise Investments (USA)
- Oncology dominates as the highest indication
- For the primary time in 2022 the aggregated deal quantity is decrease than within the earlier yr
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink